FDA Brief

Warning letters Devices

FDA warning letter to

Jiangsu Kerbio Medical Technology Group Co.

High riskIssued Jul 11, 2025Posted Aug 26, 2025Center for Devices and Radiological Health

FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

What happened

FDA inspected the testing facility from January 15 to January 24, 2025, and found violations of Good Laboratory Practice (GLP) rules for nonclinical laboratory studies of medical devices. The findings included missing daily animal observations, records showing the same staff or equipment used at overlapping times, records completed retroactively, animals reused contrary to protocols, and incomplete tracking of test articles. FDA also found quality assurance audit records did not support reported audits, and it called the company's February 21, 2025 response inadequate.

What FDA found

  1. The study director did not ensure studies followed protocols, experimental data were accurately recorded and verified, or GLP rules were followed.

    21 CFR 58.33(a), (b), and (e)
  2. The facility lacked procedures to track test article identity and document receipt and distribution of each batch.

    21 CFR 58.107(c) and (d)
  3. The quality assurance unit did not adequately inspect studies or keep records supporting reported audits, and it missed data problems.

    21 CFR 58.35(b)(3)
  4. The facility had conflicting SOPs and study directors did not authorize or document deviations from SOPs in raw data.

    21 CFR 58.81(a)

What FDA wants

FDA asks the company to promptly correct the violations and provide an adequate response with revised SOPs, training materials, audit and preventive-action plans, and evidence of effectiveness; no response deadline is stated in the letter.

Who should pay attention

  • medical device manufacturers whose devices were tested at this lab
  • sponsors relying on GLP study reports for FDA submissions
  • contract testing labs and quality assurance teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk